Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is primed for success with a diversified and promising pipeline, a strong financial position with $533.7MM in cash and cash equivalents, and a growing presence in the biopharmaceutical industry as seen through their acquisition of safusidenib rights from DaiichiSankyo. The company's future success will be heavily dependent on the commercial launch of its flagship drug Ibtrozi and the successful development of safusidenib, with potential risks including delays in clinical trial enrollment and increased competition from other biopharmaceutical companies.

Bears say

Nuvation Bio is facing several challenges that are likely to impact its financial performance, including lower-than-expected revenue from its product, taletrectinib, due to the lumpy revenue dynamics of an early-stage oncology launch and the limited market size for ROS1+ NSCLC. The company's decision to pursue all grades and types of glioma with its other product, Safusidenib, may lead to increased research and development costs, which could impact profitability in the short term. Additionally, the company's reliance on out-licensing collaborative agreements for revenue generation leaves it vulnerable to any changes in its partners' financial stability or strategic priorities.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jul 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.